

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>RUBINSTEIN JULIE</u> (Last) (First) (Middle) <u>C/O ADAPTIVE BIOTECHNOLOGIES CORP.</u> <u>SUITE 200</u> (Street) <u>SEATTLE WA 98102</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Adaptive Biotechnologies Corp [ADPT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/27/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/27/2019		M ⁽¹⁾		35,000	A	\$0.45	35,000	D	
Common Stock	12/27/2019		M ⁽¹⁾		45,000	A	\$0.45	80,000	D	
Common Stock	12/27/2019		S ⁽¹⁾		80,000	D	\$29.28 ⁽²⁾	0	D	
Common Stock	12/30/2019		M ⁽¹⁾		55,000	A	\$0.45	55,000	D	
Common Stock	12/30/2019		S ⁽¹⁾		51,500	D	\$28.51 ⁽³⁾	3,500	D	
Common Stock	12/30/2019		S ⁽¹⁾		3,500	D	\$29.12 ⁽⁴⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$0.45	12/27/2019		M ⁽¹⁾			35,000	(5)	08/21/2022	Common Stock	35,000	\$0.00	0	D	
Stock Option (Right to Buy)	\$0.45	12/27/2019		M ⁽¹⁾			45,000	(5)	02/04/2023	Common Stock	45,000	\$0.00	55,000	D	
Stock Option (Right to Buy)	\$0.45	12/30/2019		M ⁽¹⁾			55,000	(5)	02/04/2023	Common Stock	55,000	\$0.00	0	D	

Explanation of Responses:

- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$28.91 to 29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$28.04 to 28.92, inclusive.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$29.07 to 29.18, inclusive.
- The option is fully vested and exercisable.

Remarks:

/s/ Julie Rubinstein by Eric Billings, attorney-in-fact

12/31/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

